ECCO 2025

The importance of endoscopic surveillance – current…

Surgical approaches in IBD – all questions solved?

Eating is part of life – and of special therapeutic…

No treatment choices anymore? Efficacy and safety of…

New UC-kids on the block: a IL7 receptor antagonist &…

Anti-TL1a – a new treatment option in IBD and unsolved…

Comparative efficacy between biologics in UC – the need…

Combination therapies – on the way to the holy grail?

Old vs. new – ustekinumab vs. modern IL23

Update on fistulizing disease

Urgency – what is hen and what is egg?

Comparative efficacy and safety – do we need to…

Early CD treatment with vedolizumab

Dose escalation of vedolizumab in CD is not effective

Subcutaneous induction with guselkumab in CD is…

The need for early treatment in Crohn’s disease – a…

Kono-S anastomosis is not superior to side-to-side…

Subcutaneous therapy with guselkumab for Crohn's…

Subkutane Therapie mit Guselkumab bei Morbus Crohn und…

HSCT autologue – toujours une option pour la maladie de…

Rola wczesnej terapii choroby Leśniowskiego-Crohna –…

Appendectomy – a good option for UC

How to treat UC patients after failure of a s.c.…

Obefazimod maintenance treatment: a new approach

First combination of upadacitinib and vedolizumab in…

Subcutaneous therapy with guselkumab for Crohn's…

Personalized dosing in acute UC

Comment traiter la RCH après l'échec d'un anti-TNF…

Obefazimod in der Erhaltung: Neuer Ansatz

Appendektomie – eine gute Option bei Colitis Ulcerosa

Long-term efficacy and safety of a lower obefazimod…

Erste Kombination von Upadacitinib und Vedolizumab bei…

Lusvertikimab – a first-in-class IL7 receptor…

A new class of drugs: anti-TL1A antibodies

New treatments – fast forward to the future

New mode of action for treating UC

s.c.? i.v.? Just swallow it! News from the oral…

Eine neue Substanzklassen: Anti-TL1A Antikörper

s.c.? i.v.? Einfach schlucken! Neues vom oralen…

Lusvertikimab – un antagonista del recettore IL7 di…

SOR102 – un nuovo anticorpo bispecifico orale in…

Nouveau mode d'action pour le traitement de la RCH

Mirikizumab demonstrates rapid improvements in bowel…

Association between histologic response and…

Minimal Residual Disease: a new treatment goal in IBD?

What is the best treatment goal for moderate to severe…

Defining radiological healing in perianal fistulising…

Definiendo la curación radiológica en enfermedad de…

Minimal Residual Disease: ein neuer Endpunkt bei CED?

Mirikizumab demonstrates rapid improvements in bowel…

גישה כוללנית הכרחית לטיפול בחולים בדרך המיטבית

A low emulsifier diet is a treatment for moderate to…

Fibre consumption and the risk of developing CD

Tasty&Healthy – the next step towards anti-inflammatory…

Tasty&Healthy – der nächste Schritt zu einer…

PODIUM: effectiveness & safety of 2nd line vedolizumab…

Comparative efficacy of infliximab and vedolizumab…

Etrasimod improves clinical, endoscopic and histologic…

ASTRO study established the efficacy of guselkumab…

PODIUM: efficacia e sicurezza di Vedolizumab o…

El estudio ASTRO demuestra la eficacia de Guselkumab en…

Efficacia e sicurezza di una terapia combinata avanzata…

Second line treatment for perianal Crohn's disease

Dose escalation of primary non-responders is not…

Effectiveness & safety of advanced combination therapy…

Optimizing biologics in CD – is it relevant for all?

אופטימיזציה של תכשירים ביולוגים במחלת קרוהן-האם מתאים…

Zweitlinie bei Crohn-Fisteln

Mancato aumento dei livelli terapeutici di IFX nella…

Psychological factors and the risk of IBD flare

Czynniki psychologicne a ryzyko zaostrzenia IBD

How to detect preneoplastic lesions by coloscopy

αvβ6 – ein neuer Biomarker zur Prädiktion, Staging und…

HLA typing – tailoring treatment a step forward?

סיווג HLA-התקדמות בטיפול מותאם אישית?